Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06440135 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ziftomenib Maintenance Post Allo-HCT

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Sep 1, 2026 → Apr 1, 2027
See other at-risk trials from Massachusetts General Hospital

Record History

  1. Primary completion pushed from Sep 1, 2026 to Apr 1, 2027 Completion pushed from Sep 1, 2027 to Apr 1, 2029 · Eligibility criteria expanded, about 52 words · Secondary endpoints: details revised at 10 of 11 entries Show 3 more changesShow less
    • Completion pushed from Sep 1, 2027 to Apr 1, 2029
    • Eligibility criteria expanded, about 52 words
    • Secondary endpoints: details revised at 10 of 11 entries
  2. Study sites: 1 to 2 Start date: Jun 6, 2024 to Jun 11, 2024v5 Show 1 more changeShow less
    • Start date: Jun 6, 2024 to Jun 11, 2024
  3. 2 versions Re-verified since Jul 18, 2025, no change to tracked fieldsv3-v4
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 31, 2024 to Jun 6, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Aug 31, 2024 to Jun 6, 2024
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this study is: • Ziftomenib
Trial Details
NCT Number NCT06440135
Lead Sponsor Massachusetts General Hospital
Conditions Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation, KMT2A Rearrangement
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov